HAVCR2 and acute myeloid leukemia: A Novartis anti-TIM-3 antibody, MBG453 is also being evaluated as monotherapy or in combination with anti-PD-1 in patients with advanced malignancies (NCT02608268) and patients with AML or high risk myelodysplastic syndromes (NCT03066648) (Figure 2) [84].